At what fasting self‑blood glucose (FSBS) level should insulin glargine (Lantus) be held?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Holding Lantus Based on Blood Glucose Levels

Lantus (insulin glargine) should be held or reduced when fasting self-monitored blood glucose (FSBS) falls below 70 mg/dL (3.9 mmol/L), which is the established hypoglycemia alert threshold, and dose adjustments should be made to prevent recurrent hypoglycemia at this level. 1

Hypoglycemia Thresholds and Action Points

The current diabetes care guidelines define a clear hierarchy of hypoglycemia levels that should guide insulin management decisions:

  • Level 1 hypoglycemia occurs at glucose <70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L) - this is the alert value requiring treatment with fast-acting carbohydrates 1

  • Level 2 hypoglycemia occurs at glucose <54 mg/dL (3.0 mmol/L) - this represents clinically significant hypoglycemia requiring immediate treatment 1

  • Level 3 hypoglycemia is a severe event with altered mental/physical status requiring assistance from another person 1

Specific Insulin Dose Adjustment Recommendations

When FSBS values fall into hypoglycemic ranges, basal insulin should be adjusted using established titration algorithms:

  • For FSBS <4.4 mmol/L (79 mg/dL): Decrease insulin glargine by 2 units 2

  • For FSBS 4.4-7.0 mmol/L (79-126 mg/dL): No change in dose 2

  • Target FSBS range: Most titration studies aim for 4.4-5.6 mmol/L (79-101 mg/dL) or up to 7.0 mmol/L (126 mg/dL) depending on individual patient factors 3, 4, 5

Critical Clinical Considerations

Hypoglycemia unawareness or recurrent level 2/3 hypoglycemia mandates raising glycemic targets to strictly avoid hypoglycemia for at least several weeks, which helps partially reverse hypoglycemia unawareness and reduces future episode risk. 1

Several high-risk situations warrant particular vigilance and potential dose reduction or holding of Lantus:

  • Fasting states: During prolonged fasting (religious observance, medical procedures), basal insulin should be reduced to approximately 40% of total daily dose to prevent hypoglycemia 6

  • Food insecurity: Patients with unreliable food access have increased hypoglycemia-related emergency visits and require more conservative dosing 1

  • Elderly patients and young children: These populations have reduced ability to recognize and communicate hypoglycemic symptoms, requiring individualized lower glycemic targets 1

Practical Management Algorithm

When encountering low FSBS values with Lantus:

  1. At 70 mg/dL (3.9 mmol/L): Treat with 15g fast-acting carbohydrates immediately; reduce next Lantus dose by 10-20% 1

  2. Below 54 mg/dL (3.0 mmol/L): Treat hypoglycemia aggressively; hold or significantly reduce (by 20-40%) next Lantus dose pending reassessment 1

  3. Recurrent hypoglycemia pattern: Reevaluate entire insulin regimen and raise glycemic targets 1

The FDA label for Lantus does not specify exact glucose thresholds for holding the medication, but emphasizes that dose adjustments should target fasting plasma glucose ≤100 mg/dL while avoiding hypoglycemia. 7

Common Pitfalls to Avoid

  • Do not wait for severe hypoglycemia before adjusting doses - act at the 70 mg/dL threshold 1

  • Avoid overbasalization - if fasting glucose remains elevated despite high basal insulin doses (>0.5-1.0 units/kg/day), consider adding prandial insulin rather than continuing to escalate basal insulin 8

  • Ensure patients recheck glucose 15 minutes after treating hypoglycemia and repeat carbohydrate ingestion if needed 1

  • Educate patients that glucagon should be available for those at risk of severe hypoglycemia, and caregivers should know how to administer it 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.